View Older Stories View More Recent Stories
-
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
-
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
-
Medicus Pharma Ltd. To Present at Brookline Capital Markets
-
Medicus Pharma secures $8 million debenture financing for drug development
-
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
-
Medicus Pharma begins patient recruitment for UAE skin cancer trial
-
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
-
Medicus Pharma completes $2.97 million acquisition of Antev Limited
-
Medicus Pharma Ltd. Completes Acquisition of Antev Limited
-
Medicus Pharma receives FDA meeting acceptance for basal cell carcinoma drug
-
Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Secon
-
Medicus Pharma signs MOU with HelixNano for vaccine development
-
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
-
Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders
-
Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025
-
Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)
-
Medicus Pharma (MDCX) to Acquire Antev in Share Exchange Deal
-
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK
-
Medicus Pharma (MDCX) Announces Appointment of Andrew Smith as Chief Operating Officer
-
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
-
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
-
Medicus Pharma (MDCX) Submits Product Development Plan to the FDA to Treat External Squamous Cell Carcinoma in Horses
-
Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses
-
Medicus Pharma (MDCX) Closes $7M Notes Offering
-
Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering
-
Quantum BioPharma (QNTM) Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari
-
Medicus Pharma (MDCX) Announces Pricing of $7.0 Million Public Offering, 2.2M Shares at $3.10
-
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering
-
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Car
-
Medicus Pharma Ltd. (MDCX) PT Raised to $27 at D. Boral Capital
-
Medicus Pharma (MDCX) Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
-
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
-
Medicus Pharma (MDCX) Provides Update on SKNJCT-003 Phase 2 Clinical Study
-
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
-
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
-
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
-
Medicus Pharma (MDCX) Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
-
Medicus Pharma (MDCX) Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BC
-
Medicus Pharma (MDCX) Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange
-
Brookline Capital Markets Starts Medicus Pharma Ltd. (MDCX) at Buy
-
Medicus Pharma (MDCX) Announces FDA Minor Use Designation for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
-
Medicus Pharma (MDCX) Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
-
Medicus Pharma (MDCX) Appoints Faisal Mehmud as Chief Medical Officer
-
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States
-
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States
